Cargando…

CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies

Objectives. To assess CCL18 and OX40L as biomarkers of interstitial lung disease (ILD) and/or progressive fibrosing (PF-) ILD in idiopathic inflammatory myopathies (IIMs). Methods. Patients with IIMs seen in our center from July 2020 to March 2021 were consecutively enrolled. ILD was detected by hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanatta, Elisabetta, Martini, Andrea, Depascale, Roberto, Gamba, Anna, Tonello, Marta, Gatto, Mariele, Giraudo, Chiara, Balestro, Elisabetta, Doria, Andrea, Iaccarino, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217155/
https://www.ncbi.nlm.nih.gov/pubmed/37238199
http://dx.doi.org/10.3390/diagnostics13101715
_version_ 1785048469004615680
author Zanatta, Elisabetta
Martini, Andrea
Depascale, Roberto
Gamba, Anna
Tonello, Marta
Gatto, Mariele
Giraudo, Chiara
Balestro, Elisabetta
Doria, Andrea
Iaccarino, Luca
author_facet Zanatta, Elisabetta
Martini, Andrea
Depascale, Roberto
Gamba, Anna
Tonello, Marta
Gatto, Mariele
Giraudo, Chiara
Balestro, Elisabetta
Doria, Andrea
Iaccarino, Luca
author_sort Zanatta, Elisabetta
collection PubMed
description Objectives. To assess CCL18 and OX40L as biomarkers of interstitial lung disease (ILD) and/or progressive fibrosing (PF-) ILD in idiopathic inflammatory myopathies (IIMs). Methods. Patients with IIMs seen in our center from July 2020 to March 2021 were consecutively enrolled. ILD was detected by high-resolution CT. CCL18 and OX40L serum levels were measured by validated ELISA assays in 93 patients and 35 controls. At the 2-year follow-up, PF-ILD was evaluated according to the INBUILD criteria. Results. ILD was diagnosed in 50 (53.7%) patients. CCL18 serum levels were higher in IIMs patients vs. controls (232.9 [IQR 134.7–399.07] vs. 48.4 [29.9–147.5], p < 0.0001), with no difference for OX40L. IIMs-ILD patients exhibited higher levels of CCL18 than those without ILD (306.8 [190.8–520.5] vs. 162 [75.4–255.8], p < 0.0001). High CCL18 serum levels were independently associated with IIMs-ILD diagnosis. At follow-up, 22/50 (44%) patients developed a PF-ILD. Patients who developed PF-ILD had higher CCL18 serum levels than non-progressors (511 [307–958.7] vs. 207.1 [149.3–381.7], p < 0.0001). Multivariate logistic regression analysis revealed CCL18 as the only independent predictor of PF-ILD (OR 1.006 [1.002–1.011], p = 0.005). Conclusions. Although in a relatively small sample, our data suggest that CCL18 is a useful biomarker in IIMs-ILD, particularly in the early identification of patients at risk of developing PF-ILD.
format Online
Article
Text
id pubmed-10217155
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102171552023-05-27 CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies Zanatta, Elisabetta Martini, Andrea Depascale, Roberto Gamba, Anna Tonello, Marta Gatto, Mariele Giraudo, Chiara Balestro, Elisabetta Doria, Andrea Iaccarino, Luca Diagnostics (Basel) Article Objectives. To assess CCL18 and OX40L as biomarkers of interstitial lung disease (ILD) and/or progressive fibrosing (PF-) ILD in idiopathic inflammatory myopathies (IIMs). Methods. Patients with IIMs seen in our center from July 2020 to March 2021 were consecutively enrolled. ILD was detected by high-resolution CT. CCL18 and OX40L serum levels were measured by validated ELISA assays in 93 patients and 35 controls. At the 2-year follow-up, PF-ILD was evaluated according to the INBUILD criteria. Results. ILD was diagnosed in 50 (53.7%) patients. CCL18 serum levels were higher in IIMs patients vs. controls (232.9 [IQR 134.7–399.07] vs. 48.4 [29.9–147.5], p < 0.0001), with no difference for OX40L. IIMs-ILD patients exhibited higher levels of CCL18 than those without ILD (306.8 [190.8–520.5] vs. 162 [75.4–255.8], p < 0.0001). High CCL18 serum levels were independently associated with IIMs-ILD diagnosis. At follow-up, 22/50 (44%) patients developed a PF-ILD. Patients who developed PF-ILD had higher CCL18 serum levels than non-progressors (511 [307–958.7] vs. 207.1 [149.3–381.7], p < 0.0001). Multivariate logistic regression analysis revealed CCL18 as the only independent predictor of PF-ILD (OR 1.006 [1.002–1.011], p = 0.005). Conclusions. Although in a relatively small sample, our data suggest that CCL18 is a useful biomarker in IIMs-ILD, particularly in the early identification of patients at risk of developing PF-ILD. MDPI 2023-05-12 /pmc/articles/PMC10217155/ /pubmed/37238199 http://dx.doi.org/10.3390/diagnostics13101715 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zanatta, Elisabetta
Martini, Andrea
Depascale, Roberto
Gamba, Anna
Tonello, Marta
Gatto, Mariele
Giraudo, Chiara
Balestro, Elisabetta
Doria, Andrea
Iaccarino, Luca
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
title CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
title_full CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
title_fullStr CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
title_full_unstemmed CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
title_short CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
title_sort ccl18 as a biomarker of interstitial lung disease (ild) and progressive fibrosing ild in patients with idiopathic inflammatory myopathies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217155/
https://www.ncbi.nlm.nih.gov/pubmed/37238199
http://dx.doi.org/10.3390/diagnostics13101715
work_keys_str_mv AT zanattaelisabetta ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies
AT martiniandrea ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies
AT depascaleroberto ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies
AT gambaanna ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies
AT tonellomarta ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies
AT gattomariele ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies
AT giraudochiara ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies
AT balestroelisabetta ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies
AT doriaandrea ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies
AT iaccarinoluca ccl18asabiomarkerofinterstitiallungdiseaseildandprogressivefibrosingildinpatientswithidiopathicinflammatorymyopathies